Enter your information to understand your Lipoprotein(a) levels.

The History of Lipoprotein(a)

Lipoprotein(a) was first discovered in 1963 by Norwegian geneticist Kåre Berg, who identified an unusual, previously unknown genetic variant closely resembling LDL cholesterol using specialized immunological techniques, naming the newly found particle "Lp(a)" after the distinctive antigen marker he used to reliably detect it in patient blood samples tested. For several decades afterward, Lp(a) remained a relatively obscure research curiosity, since its true clinical significance wasn't yet well understood and no routine, reliable testing method existed for measuring it in ordinary clinical laboratories nationwide. That changed substantially by 2009, when the large-scale Emerging Risk Factors Collaboration published influential findings definitively establishing Lp(a) as a genuinely independent, largely genetically determined cardiovascular risk factor, distinct entirely from traditional LDL cholesterol and largely unaffected by most standard dietary and lifestyle interventions attempted by patients.

What Lipoprotein(a) Actually Is

Lipoprotein(a) is essentially an LDL particle with an additional protein, called apolipoprotein(a), permanently attached to it, a structural quirk that gives Lp(a) both cholesterol-depositing and blood-clotting properties simultaneously, a genuinely unusual combination not shared by any other common circulating lipoprotein particle. Unlike LDL and HDL, which respond meaningfully to diet, exercise, and most standard cholesterol medications, Lp(a) levels are overwhelmingly determined by inherited genetics, remaining essentially fixed throughout a person's entire adult life regardless of lifestyle changes attempted. Because elevated Lp(a) meaningfully increases cardiovascular risk independently of LDL cholesterol itself, it's considered a genuinely valuable one-time test, particularly for people with a strong family history of early, unexplained heart disease occurring at a young age.

How Lipoprotein(a) Is Measured

Lp(a) is measured using specialized immunoassay techniques, though standardizing results consistently across different laboratories has historically proven genuinely challenging, since the apolipoprotein(a) component varies considerably in size between different individuals due to a naturally occurring genetic size polymorphism inherited from birth. Because of this size variability, results are increasingly reported in nmol/L, a molar unit that more accurately reflects actual particle number, rather than the older mg/dL mass-based unit, which can meaningfully distort results depending on precisely which specific apo(a) isoform size a particular assay happens to detect during testing. Since Lp(a) levels remain remarkably stable and consistent throughout an entire life, most doctors consider a single lifetime measurement genuinely sufficient, without needing any routine repeat testing later on down the road.

Scientists Behind the Science

Kåre Berg's original 1963 discovery gave medicine its very first genuine glimpse of Lp(a) as a distinct, separately inherited lipoprotein particle, decades before anyone fully appreciated its considerable independent contribution to cardiovascular disease risk. The large international research consortiums behind the landmark 2009 Emerging Risk Factors Collaboration study later transformed that early genetic curiosity into unmistakable, statistically rigorous clinical evidence, convincingly establishing Lp(a) as a genuinely important, independent risk factor worth measuring in appropriate patients. Together, spanning nearly five decades of accumulated scientific progress, their combined work gave modern cardiology one of its most genetically informative laboratory tests for identifying inherited cardiovascular risk that traditional cholesterol testing alone simply cannot ever reliably detect on its own.